SCHEMBL13787495

SCHEMBL13787495

COc1cc2c(Oc3ncc(NC(=O)CC(=O)Nc4ccc(F)cc4)cc3Cl)ccnc2cc1OCC1CCC(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 5/20 0.54
MERTK Q12866 4/20 0.54
MET P08581 8/20 0.49
KDR P35968 8/20 0.48
PDGFRA P16234 8/20 0.48
FLT3 P36888 2/20 0.47
KIT P10721 3/20 0.46
RET P07949 2/20 0.46
DDR1 Q08345 2/20 0.46
AURKA O14965 1/20 0.46
RIPK2 O43353 1/20 0.46
ABCB11 O95342 1/20 0.46
ABL1 P00519 1/20 0.46
EGFR P00533 1/20 0.46
ERBB2 P04626 1/20 0.46
NTRK1 P04629 1/20 0.46
LCK P06239 1/20 0.46
PGR P06401 1/20 0.46
LYN P07948 1/20 0.46
CHRM2 P08172 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL374524 0.90 AXL (0.52) AXLMERTKMETKDRPDGFRA
SCHEMBL29693574 0.88 AXL (0.57) AXLMERTKMETKDRPDGFRA
SCHEMBL371576 0.88 AXL (0.57) AXLMERTKMETKDRPDGFRA
SCHEMBL29693565 0.87 AXL (0.56) AXLMERTKMETKDRPDGFRA
SCHEMBL371852 0.87 AXL (0.56) AXLMERTKMETKDRPDGFRA
SCHEMBL1788925 0.86 AXL (0.57) AXLMERTKMETKDRPDGFRA
SCHEMBL371549 0.85 AXL (0.67) AXLMERTKMETKDRPDGFRA
SCHEMBL20216630 0.83 KDR (0.52) AXLMERTKMETKDRPDGFRA
SCHEMBL20216631 0.80 MET (0.55) AXLMERTKMETKDRPDGFRA
SCHEMBL372418 0.80 AXL (0.70) AXLMERTKMETKDRFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170896-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2009-07-02 US disclosed
US-20090170896-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170896-A1 c-Met modulators and methods of use FLT4, MET, FLT1 AXL 239/4885MERTK 23/4885MET 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.